Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy</title><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name><affiliation><nlm:aff id="A1">Utah State University, Institute for Antiviral Research, Department of Animal, Dairy & Veterinary Science, 5600 Old Main Hill, Logan, UT 84322, USA</nlm:aff></affiliation></author><author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name><affiliation><nlm:aff id="A1">Utah State University, Institute for Antiviral Research, Department of Animal, Dairy & Veterinary Science, 5600 Old Main Hill, Logan, UT 84322, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">21765859</idno><idno type="pmc">3136164</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136164</idno><idno type="RBID">PMC:3136164</idno><idno type="doi">10.2217/fvl.11.33</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">000C21</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000C21</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy</title><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name><affiliation><nlm:aff id="A1">Utah State University, Institute for Antiviral Research, Department of Animal, Dairy & Veterinary Science, 5600 Old Main Hill, Logan, UT 84322, USA</nlm:aff></affiliation></author><author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name><affiliation><nlm:aff id="A1">Utah State University, Institute for Antiviral Research, Department of Animal, Dairy & Veterinary Science, 5600 Old Main Hill, Logan, UT 84322, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Future virology</title><idno type="ISSN">1746-0794</idno><idno type="eISSN">1746-0808</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in early 2003 to cause a very severe acute respiratory syndrome, which eventually resulted in a 10% case-fatality rate. Owing to excellent public health measures that isolated focus cases and their contacts, and the use of supportive therapies, the epidemic was suppressed to the point that further cases have not appeared since 2005. However, despite intensive research since then (over 3500 publications), it remains an untreatable disease. The potential for re-emergence of the SARS-CoV or a similar virus with unknown but potentially serious consequences remains high. This is due in part to the extreme genetic variability of RNA viruses such as the coronaviruses, the many animal reservoirs that seem to be able host the SARS-CoV in which reassortment or recombination events could occur and the ability coronaviruses have to transmit relatively rapidly from species to species in a short period of time. Thus, it seems prudent to continue to explore and develop antiviral chemotherapies to treat SARS-CoV infections. To this end, the various efficacious anti-SARS-CoV therapies recently published from 2007 to 2010 are reviewed in this article. In addition, compounds that have been tested in various animal models and were found to reduce virus lung titers and/or were protective against death in lethal models of disease, or otherwise have been shown to ameliorate the effects of viral infection, are also reported.</p></div></front></TEI><pmc article-type="research-article" xml:lang="en"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101278124</journal-id><journal-id journal-id-type="pubmed-jr-id">34879</journal-id><journal-id journal-id-type="nlm-ta">Future Virol</journal-id><journal-title-group><journal-title>Future virology</journal-title></journal-title-group><issn pub-type="ppub">1746-0794</issn><issn pub-type="epub">1746-0808</issn></journal-meta><article-meta><article-id pub-id-type="pmid">21765859</article-id><article-id pub-id-type="pmc">3136164</article-id><article-id pub-id-type="doi">10.2217/fvl.11.33</article-id><article-id pub-id-type="manuscript">NIHMS304163</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Barnard</surname><given-names>Dale L</given-names></name><xref ref-type="corresp" rid="cor1">†</xref><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kumaki</surname><given-names>Yohichi</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Utah State University, Institute for Antiviral Research, Department of Animal, Dairy & Veterinary Science, 5600 Old Main Hill, Logan, UT 84322, USA</aff><author-notes><corresp id="cor1"><label>†</label>Author for correspondence: Tel.: +1 435 797 2696 <email>dale.barnard@usu.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>28</day><month>6</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>3</month><year>2012</year></pub-date><volume>6</volume><issue>5</issue><fpage>615</fpage><lpage>631</lpage><permissions><copyright-statement>© 2011 Future Medicine Ltd</copyright-statement><copyright-year>2011</copyright-year></permissions><abstract><p id="P1">Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in early 2003 to cause a very severe acute respiratory syndrome, which eventually resulted in a 10% case-fatality rate. Owing to excellent public health measures that isolated focus cases and their contacts, and the use of supportive therapies, the epidemic was suppressed to the point that further cases have not appeared since 2005. However, despite intensive research since then (over 3500 publications), it remains an untreatable disease. The potential for re-emergence of the SARS-CoV or a similar virus with unknown but potentially serious consequences remains high. This is due in part to the extreme genetic variability of RNA viruses such as the coronaviruses, the many animal reservoirs that seem to be able host the SARS-CoV in which reassortment or recombination events could occur and the ability coronaviruses have to transmit relatively rapidly from species to species in a short period of time. Thus, it seems prudent to continue to explore and develop antiviral chemotherapies to treat SARS-CoV infections. To this end, the various efficacious anti-SARS-CoV therapies recently published from 2007 to 2010 are reviewed in this article. In addition, compounds that have been tested in various animal models and were found to reduce virus lung titers and/or were protective against death in lethal models of disease, or otherwise have been shown to ameliorate the effects of viral infection, are also reported.</p></abstract><kwd-group><kwd>animal models</kwd><kwd>antiviral</kwd><kwd>chemotherapy</kwd><kwd>coronavirus</kwd><kwd><italic>in vivo</italic> inhibitors</kwd><kwd>SARS-CoV</kwd><kwd>SARS inhibitors</kwd><kwd>severe acute respiratory syndrome</kwd></kwd-group><funding-group><award-group><funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source><award-id>N01 AI030048 || AI</award-id></award-group><award-group><funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source><award-id>N01 AI015435 || AI</award-id></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000C21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |